Salveen Richter
Stock Analyst at Goldman Sachs
(2.35)
# 2,546
Out of 4,761 analysts
200
Total ratings
41.44%
Success rate
-0.19%
Average return
Main Sectors:
Stocks Rated by Salveen Richter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $66 → $57 | $50.43 | +13.03% | 3 | Feb 13, 2025 | |
| BIIB Biogen | Maintains: Buy | $281 → $245 | $137.08 | +78.73% | 3 | Feb 13, 2025 | |
| GILD Gilead Sciences | Maintains: Neutral | $85 → $96 | $110.03 | -12.75% | 5 | Feb 12, 2025 | |
| MRNA Moderna | Downgrades: Neutral | $99 → $51 | $33.73 | +51.20% | 10 | Jan 29, 2025 | |
| DNLI Denali Therapeutics | Maintains: Buy | $45 → $40 | $21.59 | +85.27% | 5 | Jan 28, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Neutral | $5.5 → $7.5 | $8.33 | -9.96% | 9 | Jan 28, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $20 → $12 | $12.25 | -2.04% | 8 | Jan 14, 2025 | |
| APLS Apellis Pharmaceuticals | Downgrades: Neutral | $36 | $28.35 | +26.98% | 7 | Dec 17, 2024 | |
| QURE uniQure | Maintains: Neutral | $9 → $20 | $12.96 | +54.32% | 7 | Dec 12, 2024 | |
| INCY Incyte | Maintains: Neutral | $63 → $70 | $71.38 | -1.93% | 9 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $4.09 | +389.00% | 2 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $198 → $370 | $251.00 | +47.41% | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $76 | $44.48 | +70.86% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $33 → $37 | $32.69 | +13.18% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $11 | $7.15 | +53.85% | 11 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $53 | $33.75 | +57.04% | 9 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $313 → $350 | $297.93 | +17.48% | 7 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $81 | $4.67 | +1,634.48% | 3 | Feb 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $442 → $559 | $480.33 | +16.38% | 4 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $5 | $2.68 | +86.57% | 4 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4.5 → $5 | $16.75 | -70.15% | 5 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $188 → $215 | $108.41 | +98.32% | 3 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $11 | $9.07 | +21.28% | 1 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $31 | $2.26 | +1,274.72% | 7 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $257 → $225 | $291.02 | -22.69% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $22 | $3.13 | +602.88% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.66 | - | 4 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $30 | $5.89 | +409.34% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $14 | $1.02 | +1,272.55% | 3 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $9 | $10.35 | -13.04% | 6 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $3 | $1.64 | +82.93% | 4 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $15 → $12 | $20.29 | -40.86% | 8 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $6 | $3.06 | +96.08% | 3 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $39 → $43 | $59.67 | -27.94% | 1 | Oct 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $796 → $970 | $696.02 | +39.36% | 9 | Oct 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $40 → $60 | $7.04 | +752.27% | 6 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $4 | $0.15 | +2,497.40% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $3 → $2 | $1.54 | +29.87% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $125 → $100 | $7.52 | +1,229.79% | 1 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $48 → $28 | $10.74 | +160.71% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $28 → $30 | $0.55 | +5,354.55% | 3 | Mar 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $57 → $50 | $106.46 | -53.03% | 4 | Mar 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $45 | $20.96 | +114.69% | 1 | Mar 17, 2020 |
CRISPR Therapeutics AG
Feb 13, 2025
Maintains: Neutral
Price Target: $66 → $57
Current: $50.43
Upside: +13.03%
Biogen
Feb 13, 2025
Maintains: Buy
Price Target: $281 → $245
Current: $137.08
Upside: +78.73%
Gilead Sciences
Feb 12, 2025
Maintains: Neutral
Price Target: $85 → $96
Current: $110.03
Upside: -12.75%
Moderna
Jan 29, 2025
Downgrades: Neutral
Price Target: $99 → $51
Current: $33.73
Upside: +51.20%
Denali Therapeutics
Jan 28, 2025
Maintains: Buy
Price Target: $45 → $40
Current: $21.59
Upside: +85.27%
Adaptive Biotechnologies
Jan 28, 2025
Maintains: Neutral
Price Target: $5.5 → $7.5
Current: $8.33
Upside: -9.96%
Intellia Therapeutics
Jan 14, 2025
Maintains: Neutral
Price Target: $20 → $12
Current: $12.25
Upside: -2.04%
Apellis Pharmaceuticals
Dec 17, 2024
Downgrades: Neutral
Price Target: $36
Current: $28.35
Upside: +26.98%
uniQure
Dec 12, 2024
Maintains: Neutral
Price Target: $9 → $20
Current: $12.96
Upside: +54.32%
Incyte
Oct 30, 2024
Maintains: Neutral
Price Target: $63 → $70
Current: $71.38
Upside: -1.93%
Sep 10, 2024
Reinstates: Buy
Price Target: $20
Current: $4.09
Upside: +389.00%
Aug 16, 2024
Upgrades: Buy
Price Target: $198 → $370
Current: $251.00
Upside: +47.41%
Aug 2, 2024
Maintains: Buy
Price Target: $67 → $76
Current: $44.48
Upside: +70.86%
Aug 2, 2024
Maintains: Sell
Price Target: $33 → $37
Current: $32.69
Upside: +13.18%
Jul 26, 2024
Maintains: Neutral
Price Target: $19 → $11
Current: $7.15
Upside: +53.85%
Jun 4, 2024
Maintains: Neutral
Price Target: $33 → $53
Current: $33.75
Upside: +57.04%
Feb 8, 2024
Maintains: Buy
Price Target: $313 → $350
Current: $297.93
Upside: +17.48%
Feb 7, 2024
Reinstates: Buy
Price Target: $81
Current: $4.67
Upside: +1,634.48%
Jan 31, 2024
Maintains: Buy
Price Target: $442 → $559
Current: $480.33
Upside: +16.38%
Sep 13, 2023
Downgrades: Neutral
Price Target: $5
Current: $2.68
Upside: +86.57%
Aug 15, 2023
Maintains: Neutral
Price Target: $4.5 → $5
Current: $16.75
Upside: -70.15%
Jun 23, 2023
Maintains: Buy
Price Target: $188 → $215
Current: $108.41
Upside: +98.32%
Mar 2, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $9.07
Upside: +21.28%
Mar 2, 2023
Maintains: Buy
Price Target: $35 → $31
Current: $2.26
Upside: +1,274.72%
Feb 24, 2023
Maintains: Overweight
Price Target: $257 → $225
Current: $291.02
Upside: -22.69%
Nov 14, 2022
Initiates: Neutral
Price Target: $22
Current: $3.13
Upside: +602.88%
Nov 11, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.66
Upside: -
Nov 10, 2022
Maintains: Neutral
Price Target: $60 → $30
Current: $5.89
Upside: +409.34%
Nov 10, 2022
Maintains: Buy
Price Target: $25 → $14
Current: $1.02
Upside: +1,272.55%
Nov 9, 2022
Maintains: Neutral
Price Target: $8 → $9
Current: $10.35
Upside: -13.04%
Nov 9, 2022
Downgrades: Neutral
Price Target: $16 → $3
Current: $1.64
Upside: +82.93%
Nov 4, 2022
Downgrades: Sell
Price Target: $15 → $12
Current: $20.29
Upside: -40.86%
Nov 3, 2022
Maintains: Neutral
Price Target: $7 → $6
Current: $3.06
Upside: +96.08%
Oct 28, 2022
Maintains: Neutral
Price Target: $39 → $43
Current: $59.67
Upside: -27.94%
Oct 3, 2022
Maintains: Buy
Price Target: $796 → $970
Current: $696.02
Upside: +39.36%
Aug 19, 2022
Maintains: Sell
Price Target: $40 → $60
Current: $7.04
Upside: +752.27%
May 24, 2022
Maintains: Neutral
Price Target: $7 → $4
Current: $0.15
Upside: +2,497.40%
May 24, 2022
Maintains: Sell
Price Target: $3 → $2
Current: $1.54
Upside: +29.87%
May 24, 2022
Maintains: Sell
Price Target: $125 → $100
Current: $7.52
Upside: +1,229.79%
May 12, 2022
Maintains: Neutral
Price Target: $48 → $28
Current: $10.74
Upside: +160.71%
Mar 4, 2021
Upgrades: Buy
Price Target: $28 → $30
Current: $0.55
Upside: +5,354.55%
Mar 19, 2020
Maintains: Neutral
Price Target: $57 → $50
Current: $106.46
Upside: -53.03%
Mar 17, 2020
Initiates: Neutral
Price Target: $45
Current: $20.96
Upside: +114.69%